Provided by Tiger Trade Technology Pte. Ltd.

BRIACELL THERAPEUTICS CORP C/WTS (TO PUR COM) 15/01/2031

1.09
+0.09019.01%
Post-market: 1.090.00000.00%16:18 EDT
Volume:35.86K
Turnover:38.65K
Market Cap:- -
PE:- -
High:1.11
Open:1.00
Low:0.9950
Close:0.9999
52wk High:1.40
52wk Low:0.6100
Shares:- -
Float Shares:- -
Volume Ratio:4.93
T/O Rate:- -
Dividend:- -
Dividend Rate:- -
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Briacell Receives FDA Clearance to Initiate Bria-Pros+™ Clinical Study in Prostate Cancer

THOMSON REUTERS
·
Aug 05

Briacell Opens First Canadian Site – Sunnybrook – for Pivotal Phase 3 Trial in Metastatic Breast Cancer

THOMSON REUTERS
·
Jul 16

Briacell Therapeutics Corp - Arrangement Provides Manufacturing Capacity for Phase 3 Study and Commercial Scalability

THOMSON REUTERS
·
Jul 15

Briacell Therapeutics Corp - Announces Manufacturing Arrangement with Fujifilm Biotechnologies California for Bria-imt

THOMSON REUTERS
·
Jul 15

Briacell Therapeutics Announces Closing of Offering

THOMSON REUTERS
·
Jun 03

BRIEF-Briacell Therapeutics Prices 1.45 Million Common Shares At $3.25 Per Share

Reuters
·
Jun 01

Briacell Therapeutics Announces Pricing of Offering

THOMSON REUTERS
·
Jun 01

Briacell Therapeutics Corp - Interim Topline Data From Phase 3 Bria-Abc Study Expected in 2026

THOMSON REUTERS
·
May 12

Briacell Phase 3 Bria-Imt™ Study Enrollment Surpasses 230 Patients

THOMSON REUTERS
·
May 12

Briacell Therapeutics Corp - to Initiate Phase 1/2a Study of Bria-Bres+ in Coming Months

THOMSON REUTERS
·
May 06

Briacell Receives FDA Clearance to Initiate Bria-Bres+™ Clinical Study in Breast Cancer

THOMSON REUTERS
·
May 06

BRIEF-Briacell, Briapro Enter Into Asset Purchase Agreement For Exclusive Soluble CD80 License

Reuters
·
Feb 19

Briacell and Briapro Enter Into Asset Purchase Agreement for Exclusive Soluble Cd80 License

THOMSON REUTERS
·
Feb 19

Briacell Therapeutics Corp - Briapro to Pay 2% Royalties to Umbc Upon Commercialization

THOMSON REUTERS
·
Feb 19